Results 121 to 130 of about 24,744 (229)

A retrospective sub‐study of perioperative glycaemia and insulin treatment for hospital inpatients at a quaternary centre from the specialist treatment of inpatients: Caring for diabetes in surgery trial (STOIC‐D Surgery)

Diabetic Medicine, Volume 43, Issue 8, August 2026.
Abstract Aims Surgical inpatients experience variable glycaemia, with hyper and hypoglycaemia, contributing towards increased morbidity and mortality. Understanding of mechanisms for glycaemic variability and clinician responses remains limited. We aimed to describe patterns of glycaemia in the immediate perioperative period and its drivers, including ...
Florence Ho, Mervyn Kyi, Spiros Fourlanos, Peter G. Colman, Leon J. Worth, Rahul D. Barmanray   +5 more
wiley   +1 more source

Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis” [PDF]

Clinical and Molecular Hepatology
Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim   +3 more
doaj   +1 more source

Polypharmacy and Bone Health in Patients with Type 2 Diabetes Mellitus: A Narrative Review. [PDF]

J Bone Metab
Kashmoola IO, Mohammad SH, Alsaaty MH.
europepmc   +1 more source

Association Between SGLT2 Inhibitors and DPP‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6767-6775, August 2026.
ABSTRACT Aims The Korean national health insurance claims database was utilised to investigate the association between sodium–glucose cotransporter 2 inhibitors (SGLT2i) or dipeptidyl peptidase‐4 inhibitors (DPP‐4i) and the risk of acute pancreatitis (AP). Materials and Methods Patients with type 2 diabetes mellitus prescribed DPP‐4i or SGLT2i at least
Ye‐Jee Kim, Yun Kyung Cho, Mi‐Sook Kim, Joongyub Lee, Seonghae Kim, Bo Ram Yang   +5 more
wiley   +1 more source

Sodium-glucose co-transporter 2 inhibitors are negatively correlated with hypomagnesemia in elderly patients with type 2 diabetes. [PDF]

Front Nutr
Lin L, Jin Y, Jin L, Wang B, Xu J, Chen S.   +5 more
europepmc   +1 more source

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6509-6532, August 2026.
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano, Line L. Haurum, Christine R. Schwarz, Francesca Porcellati, Andreas Andersen   +4 more
wiley   +1 more source

The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6874-6887, August 2026.
ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh, Brandon Michael Henry, István Édes   +2 more
wiley   +1 more source

From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies. [PDF]

Endocrine
Modica R, Liccardi A, Zamponi V, Gagliardi A, Nistor A, Veroi G, Arecco A, Faggiano A, Colao A.   +8 more
europepmc   +1 more source

Trends in Second‐Line Initiations and Treatment Outcomes Across Age and Frailty Groups in People With Type 2 Diabetes: UK Population‐Based Study, 2019–2024

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7471-7482, August 2026.
ABSTRACT Aims To assess contemporary UK trends in second‐line treatment initiations and outcomes across age‐and‐frailty groups in people with type 2 diabetes (T2D). Materials and Methods We studied 117 046 UK adults with T2D initiating second‐line therapy between 2019–2024 (Clinical Practice Research Datalink).
M. M. Dinsdale, K. G. Young, P. Cardoso, L. M. Güdemann, T. T. Jansz, A. P. McGovern, A. G. Jones, E. R. Pearson, A. T. Hattersley, T. J. McKinley, B. M. Shields, J. M. Dennis   +11 more
wiley   +1 more source

Incidence and risk factors for osteoporosis in people with type 2 diabetes mellitus in Thailand. [PDF]

BMC Endocr Disord
Sribenjalak D, Looareesuwan P, Siriyotha S, Sritara C, Amnuaywattakorn S, Ongphiphadhanakul B, Thakkinstian A, Nimitphong H.   +7 more
europepmc   +1 more source